ArticleInfection and immunity2020
Major Histocompatibility Complex Class II-Restricted, CD4
Article in Infection and immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Article
- Review
- Role of Type 4B Secretion System Protein, IcmE, in the Pathogenesis ofPathogens (Basel, Switzerland) · 2024Article
- Article
- Q fever immunology: the quest for a safe and effective vaccine.NPJ vaccines · 2023Review
- Cytometry profiling ofFrontiers in immunology · 2023Article
- Virus Detection: From State-of-the-Art Laboratories to Smartphone-Based Point-of-Care Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Immunogenicity and Reactogenicity in Q Fever Vaccine Development.Frontiers in immunology · 2022Review
- Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models ofFrontiers in immunology · 2022Article
- Cross-reactivity between vaccine antigens from the chitin deacetylase protein family improves survival in a mouse model of cryptococcosis.Frontiers in immunology · 2022Article
- Q Fever Vaccine Development: Current Strategies and Future Considerations.Pathogens (Basel, Switzerland) · 2021Review
- Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity.NPJ vaccines · 2021Article
- The Feasibility of UsingFrontiers in immunology · 2021Article
- Failure of CD4 T Cell-Deficient Hosts To Control Chronic NontyphoidalInfection and immunity · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
To understand the role of major histocompatibility complex class I (MHC-I) and MHC-II in vaccine-mediated protection against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.